The impact of pre-transplant body weight on outcomes after allogeneic hematopoietic cell transplantation (allo-HCT) remains controversial, and available data are limited by the use of different classification tools and the arbitrary determination of cutoff values. Most working groups have applied similar but slightly different body mass index (BMI) classifications according to the World Health Organization (WHO BMI) and the remainder employed very different cutoff values from the ratio of actual to ideal body weight (IBW). [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] Furthermore, the follow-up period for outcomes considered in one part of the studies covered at most the first post transplant year. 3, 6, 9, 10 This therefore reveals the strengths of the present retrospective analysis, as we investigated for the first time the validity of three different weight classification tools using standard cutoffs as pretransplant prognostic factors, a long follow-up period of 7.2 years and a consistent chemotherapy dose adjustment in obese patients (Table 1) compared with most other studies with no adjustment or relevant information. [1] [2] [3] 5, 9, 11 The considered outcomes were overall survival (OS), PFS, relapse, nonrelapse mortality (NRM), acute GvHD (aGvHD) and chronic GvHD (cGvHD) and leukocyte engraftment. Beside the standard BMI classification of the WHO and IBW calculated using Devine's equation (Table 1) , we also captured age-and gender-adjusted BMI percentiles (adjusted BMI) of a current, representative German reference population. 12 This allowed us to further categorize each BMI value as low (o 10th percentile), normal (10-90th percentile) or high (490th percentile).
From January 1996 to December 2011, 1190 consecutive adults with median age of 51 years admitted for their first allo-HCT at our center were included. Patient, disease and transplant characteristics are described in Table 1 . Cross-tabulations (data not shown) revealed a conspicuous classification shift of decrease in overweight and increase in underweight from the tools referring to IBW, WHO BMI and to adjusted BMI. As of December 2011, 495 (41.6%) patients were alive. The attributed causes of death were relapse/progression (52.4%), infection (23.1%), GvHD (8.9%), organ failure (5.9%), hemorrhage (2.8%), secondary malignancy (2.7%), other (2.9%), graft failure (0.3%) and unknown (1%).
Kaplan-Meier estimates for OS and PFS, and cumulative incidence rates (Aalen-Johanson estimator) for NRM and relapse probabilities of the different weight classifications at allo-HCT by each tool are presented in Figure 1 , respectively. The standard and most frequently used tool is the WHO BMI and weight classification using IBW as reference that only revealed significantly different probabilities of NRM and relapse between groups, whereas the BMI classification based on age-and gender-adjusted BMI percentiles (adjusted BMI) demonstrated prognostic relevance for OS, PFS and relapse. Adjusted BMI performed best in this evaluation, revealing the importance of considering the age and gender dependencies of BMI. There is a larger part of the population in higher BMI intervals with increasing age. Closer examination of the representative BMI percentiles shows that in adult females, the 10th and 90th percentiles of BMI shifts with increasing age from 18.7 to 22.9 kg/m Cox regression models providing hazard ratios (HRs) for OS and PFS, and Fine and Gray regression models rendering subdistribution hazard ratios (SHRs) for NRM, relapse, aGvHD, cGVHD and engraftment time were applied to assess the impact of weight classification tools in the presence of other relevant prognostic factors. The prognostic factors considered were: serum albumin and C-reactive protein (CRP), recipient and donor age and gender, CMV infection risk, diagnosis, male recipient/female donor vs others, HLA compatibility, disease status, conditioning regimen and time between diagnosis and allo-HCT. Possible prognostic factors with a univariate Po0.1 and the weight classification variable as a hypothesis variable were entered in a multivariate regression model. A variable selection method (backward elimination with Po0.05) was then performed, keeping the hypothesis variable fixed in the model. We decided to conduct multivariate analyses for adjusted BMI, as this tool detects univariate differences in analyzed outcomes better than the other two.
Multivariate analysis showed that patients in the low adjusted BMI group revealed a tendency toward higher risk of mortality (HR 1.19 (95% confidence interval (CI), 0.99-1.43), P = 0.07). Besides familiar prognostic factors such as older recipient's age, HLA mismatch, lymphatic disease and advanced disease, low serum albumin (HR 1.30 (95% CI, 1.08-1.57), P = 0.006) and increased CRP (HR 1.26 (95% CI, 1.07-1.49), P = 0.005) were independently associated with lower overall survival. HLA mismatch, lymphatic and advanced disease, albumin and CRP were significantly associated and patients in the low adjusted BMI group showed a tendency toward (HR 1.18 (95% CI, 0.99-1.41), P = 0.06) lower PFS, respectively. Together with five other prognostic factors, patients with adjusted BMI classified as high (SHR 1.50 (95% CI, 1.00-2.26), P = 0.05) had significantly increased NRM. The probability of relapse was significantly lower only in the high adjusted BMI group (SHR 0.50 (95% CI, 0.30-0.83), P = 0.008), and was higher in patients with advanced disease status. Furthermore, the high adjusted BMI group displayed a higher risk for aGvHD (SHR 1.73 (95% CI, 1.20-2.50), P = 0.003). Other factors associated with aGvHD were CRP and donor HLA-C. We observed no associations between adjusted BMI and cGvHD or time to engraftment.
Our multivariate analysis showed that overweight (adjusted BMI 490th percentile) was associated with a higher risk of grade II-IV aGvHD, in line with results from a recent meta-analysis. 13 The overweight group was protected from relapse. However, this benefit was offset by excessive NRM, leading to this study's major finding, namely that overweight demonstrate no difference in impact on OS compared with normal-weight patients. Many retrospective analyses have investigated the association between pre-transplant body weight and outcome in patients undergoing Abbreviations: allo-HCT = allogeneic hematopoietic cell transplantation; BM = bone marrow; BMI = body mass index; CRP = C-reactive protein; D = donor; MDS = myelodysplastic syndrome; MM = multiple myeloma; MPN = myeloproliferative neoplasm; NHL = non-Hodgkin's lymphoma; R = recipient. d In all, 162 (13.6%) had undergone one (n = 44) or more (n = 18) previous autologous transplantations. e Three patients were under 18 years of age (1 × 16 and 2 × 17) but as the reference population's 12 data set included only adults, we assumed an age of 18 years for these minors. Letter to the Editor allo-HCT, with inconsistent results. Obesity was found in adults undergoing allo-HCT to reduce OS, increase NRM and the risk of infections. 2, 6, 10, 11, 14 However, other studies detected no association between obesity and OS. 1, 2, [4] [5] [6] [7] 9 A recent metaanalysis by Nakao et al. 13 focused on the overweight impact on HCT outcomes. By pooling pediatric and adult allo-HCT studies, overweight at transplantation was associated with worse OS and a higher aGvHD rate. Unfortunately, their meta-analysis could not include the largest study on this topic published the same year by Fuji et al.
14 with 12 050 adults undergoing allo-HCT. Overweight patients had the highest NRM but no inferior OS than normal-weight patients. Were the meta-analysis by Nakao et al., 13 the present study data and those from Fuji et al. 14 pooled today, overweight would very likely no longer be associated with worse survival. However, Fuji et al. 14 did identify underweight as a prognostic factor for poor OS because of an increased risk of relapse.
Underweight patients (low adjusted BMI) also experienced decreased PFS and a trend toward lower OS (P = 0.07) in this multivariate analysis. It is noteworthy that on closer inspection of the available data in allo-HCT adults, we noted that all those studies designed and able to investigate the impact of underweight revealed its significant negative association with OS or engraftment time.
1,3-5,9,14 Our results completely support the often overlooked fact that underweight, and not overweight, is the less favorable pre-condition. Several retrospective analyses neglected the underweight patients and failed to accommodate them in the study design, and thus the impact of underweight went unaddressed because no underweight patients were included in the studied population, or those underweight were mixed with normal-weight patients. 6, 10, 11 The underlying mechanism is certainly multifactorial and in-depth investigations are lacking. The most obvious factor might be their less ample 'biologic reserve' to tolerate the nutritional disruption during highdose chemotherapy. It must be emphasized that underweight does not automatically imply malnourishment.
In summary, our results suggest that pre-transplant obesity is not associated with worse OS independent of the weight classification tool used. However, patients with low body weight revealed a tendency toward lower OS. The key clinical significances of our findings are that obesity alone should not exclude patients from consideration for allo-HCT and that body weight is theoretically modifiable during the often-lengthy treatment period before transplantation compared with most other prognostic factors. Our data also demonstrate the inferiority of the WHO standard BMI classification and the IBW classification compared with adjusted BMI as a pre-transplant outcome predictor. Weight classification based on age-and genderadjusted BMI percentiles is the most suitable means of overriding the weakness of the fixed WHO classification that fails to consider dynamic changes and gender-specific differences in body weight during the entire lifespan. Future prognostic factor studies in cancer patients should pay greater attention to underweight as a prognostic variable.
